Donanemab exposure-response in early symptomatic Alzheimer's disease. Gueorguieva I, Chow K, Chua L, Shcherbinin S, et al. Alzheimers Dement 2025;21:e70491.

Read + Share

Amedeo Smart

Independent Medical Education

Gueorguieva I, Chow K, Chua L, Shcherbinin S, et al. Donanemab exposure-response in early symptomatic Alzheimer's disease. Alzheimers Dement 2025;21:e70491.
PMID: 40667684